Pfizer Inc.
General ticker "PFE" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $141.3B (TTM average)
Pfizer Inc. follows the US Stock Market performance with the rate: 26.6%.
Estimated limits based on current volatility of 1.0%: low 25.31$, high 25.82$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-11-07, amount 0.43$ (Y6.69%)
- Total employees count: 81000 (-8.0%) as of 2024
- US accounted for 60.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Pandemic risks, Supply chain disruptions, Climate change and natural disasters, Economic downturns and volatility, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [23.09$, 34.15$]
- 2025-12-31 to 2026-12-31 estimated range: [25.82$, 37.71$]
Financial Metrics affecting the PFE estimates:
- Positive: with PPE of 8.5 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 25.91 > 18.64
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 8.11
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.64
- Positive: 6.82 < Operating cash flow per share per price, % of 8.52
- Positive: Industry operating profit margin (median), % of 20.85 > 9.92
- Negative: 0.79 < Interest expense per share per price, % of 2.07
Short-term PFE quotes
Long-term PFE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $100,330.00MM | $59,553.00MM | $63,627.00MM |
| Operating Expenses | $62,781.00MM | $54,261.00MM | $47,144.00MM |
| Operating Income | $37,549.00MM | $5,292.00MM | $16,483.00MM |
| Non-Operating Income | $-2,820.00MM | $-4,234.00MM | $-8,460.00MM |
| Interest Expense | $1,238.00MM | $2,209.00MM | $3,091.00MM |
| R&D Expense | $11,426.00MM | $10,578.00MM | $10,738.00MM |
| Income(Loss) | $34,729.00MM | $1,058.00MM | $8,023.00MM |
| Taxes | $3,328.00MM | $-1,114.00MM | $-28.00MM |
| Other Income(Loss) | $6.00MM | $-15.00MM | $0.00MM |
| Profit(Loss)* | $31,365.00MM | $2,133.00MM | $8,020.00MM |
| Stockholders Equity | $95,661.00MM | $89,014.00MM | $88,203.00MM |
| Inventory | $8,981.00MM | $10,189.00MM | $10,851.00MM |
| Assets | $197,205.00MM | $226,501.00MM | $213,396.00MM |
| Operating Cash Flow | $29,267.00MM | $8,700.00MM | $12,744.00MM |
| Capital expenditure | $3,236.00MM | $3,907.00MM | $2,909.00MM |
| Investing Cash Flow | $-15,783.00MM | $-32,278.00MM | $2,652.00MM |
| Financing Cash Flow | $-14,834.00MM | $26,066.00MM | $-17,140.00MM |
| Earnings Per Share** | $5.59 | $0.38 | $1.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.